8-Bromo-1-(1,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-one → HCID 59620036, 화합물
반응식
Br[C:2]1[CH:11]=[CH:10][C:9]2[N:8]=[CH:7][C:6]3[N:12]([CH3:23])[C:13](=[O:22])[N:14]([C:15]4[C:16]([CH3:21])=[N:17][N:18]([CH3:20])[CH:19]=4)[C:5]=3[C:4]=2[CH:3]=1.[N:24]1([C:28]2[CH:33]=[CH:32][C:31](B3OC(C)(C)C(C)(C)O3)=[CH:30][N:29]=2)[CH2:27][CH2:26][CH2:25]1>>[N:24]1([C:28]2[N:29]=[CH:30][C:31]([C:2]3[CH:11]=[CH:10][C:9]4[N:8]=[CH:7][C:6]5[N:12]([CH3:23])[C:13](=[O:22])[N:14]([C:15]6[C:16]([CH3:21])=[N:17][N:18]([CH3:20])[CH:19]=6)[C:5]=5[C:4]=4[CH:3]=3)=[CH:32][CH:33]=2)[CH2:27][CH2:26][CH2:25]1참가 물질
3
실험 절차
The title compound was synthesized in a similar manner as described for Example 1.1 using 8-bromo-1-(1,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-one (Intermediate A, 40 mg, 0.107 mmol) and 2-azetidin-1-yl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridine (Stage 5.1.1, 39 mg, 0.150 mmol) to give the title compound as a white solid. (HPLC: tR 2.24 min (Method A); M+H=426 MS-ES; 1H-NMR (d6-DMSO, 400 MHz) 8.91 (s, 1H), 8.25-8.18 (m, 1H), 8.14-8.09 (m, 1H), 8.06-8.02 (m, 1H), 7.89-7.81 (m, 1H), 7.62-7.53 (m, 1H), 7.42 (s, 1H), 6.48-6.42 (m, 1H), 4.01-3.93 (m, 4H), 3.91 (s, 3H), 3.56 (s, 3H), 2.36-2.28 (m, 2H), 1.96 (s, 3H))